Search results for "Drug Combination"

showing 10 items of 197 documents

The Effects of Prostaglandin E-1 in Patients with Intermittent Claudication

2006

Aim of the study is to evaluate the effects of Prostaglandin E-1 (PGE-1) in patients with peripheral arterial disease (PAD) at the 2nd b stage Fontaines classification. The study, controlled, single blinded, enrolled 123 patients with intermittent claudication that were randomised in two groups; the first group received a treatment with PGE-1 while the second one received a pentoxifylline-buflomedil association by venous infusion. We evaluated: Pain Free Walking Distance (PFWD), Maximum Walking Distance (MWD), Rest Flow (RF), Peak Flow (PF), Basal (BVR) and Minimal Vascular Resistance (MVR) with a strain gauge plethysmograph, Resting Flow (RF), Peak Flow (PF), time to reach the Peak Flow (t…

AdultMalemedicine.medical_specialtyPyrrolidinesVasodilator AgentsProstaglandinHemodynamicsWalkingSeverity of Illness IndexMicrocirculationchemistry.chemical_compoundInternal medicineLaser-Doppler FlowmetrymedicineHumansPlethysmographAlprostadilPentoxifyllineInfusions IntravenousAgedPharmacologybusiness.industryHematologyGeneral MedicineIntermittent ClaudicationMiddle AgedLaser Doppler velocimetryIntermittent claudicationSurgeryPeripheralPlethysmographyDrug CombinationsTreatment Outcomemedicine.anatomical_structurechemistryRegional Blood FlowExercise TestVascular resistanceCardiologyMolecular MedicineFemaleVascular Resistancemedicine.symptomCardiology and Cardiovascular MedicinebusinessCardiovascular & Hematological Disorders-Drug Targets
researchProduct

Efficacy, safety and quality of life of calcipotriol/betamethasone dipropionate (Dovobet (R)) versus calcipotriol (Daivonex (R)) in the treatment of …

2007

Objective: A clinical trial was performed to evaluate the efficacy, speed of response, side effects and quality of life of patients treated with calcipotriol/betamethasone dipropionate (Dovobet (R)) for 4 weeks followed by maintenance with calcipotriol for 8 weeks (group A) versus calcipotriol (Daivonex (R)) alone for 12 weeks (group B) for the treatment of psoriasis. Materials and methods: A total of 150 patients were enrolled and randomized to groups A and B. PASI and Skindex-29 were considered the outcome measures. Results: Ninety-six patients completed the trial. At weeks 2 and 4, both groups showed a significant clinical improvement compared to baseline; group A demonstrated a higher c…

AdultMalemedicine.medical_specialtyRandomizationAdolescentskindex-29medicine.drug_classBetamethasone dipropionatecalcipotriol/betamethasone dipropionate; Dovobet; calcipotriol. Daivonex; psoriasis vulgaris; clinical trialDermatologyAdministration CutaneousBetamethasoneSeverity of Illness IndexDrug Administration Schedulelaw.inventionchemistry.chemical_compoundRandomized controlled trialCalcitriolcalcipotriolo/betametasone dipropionatolawPsoriasisInternal medicinepasimedicineHumansPsoriasiscalcipotriolo; calcipotriolo/betametasone dipropionato; pasi; psoriasi; skindex-29CalcipotriolcalcipotriolopsoriasiAgedAged 80 and overAnalysis of Variancebusiness.industrycalcipotriol calcipotriol/betamethasone dipropionate PASI psoriasis Skindex-29 two-compound productMiddle Agedmedicine.diseaseSurgeryClinical trialDrug CombinationsTreatment OutcomechemistryQuality of LifeCorticosteroidBetamethasoneFemaleDermatologic Agentsbusinessmedicine.drug
researchProduct

Prevention of deep vein thrombosis in neurosurgical patients: a prospective double-blind comparison of two prophylactic regimen.

1992

In a prospective, randomized, double-blind investigation of anticoagulant agents for prevention of deep vein thrombosis in patients undergoing operations at the lumbar-vertebral disc, 179 patients were randomly allocated to two groups. 87 patients received a fixed combination of low-molecular weight heparin 1,500 U-aPTT plus dihydroergotamine 0.5 mg (LMWH/DHE) once a day and additionally one injection of placebo per day, 92 patients received a fixed combination of sodium heparin 5,000 U plus dihydroergotamine 0.5 mg (HDHE) twice a day. Treatment was initiated two hours preoperatively in both groups and continued for at least seven days. Deep vein thrombosis (DVT), detected by the 125Iodine-…

AdultMalemedicine.medical_specialtymedicine.drug_classDeep veinLow molecular weight heparinHemorrhageDihydroergotaminePostoperative ComplicationsDouble-Blind MethodRisk FactorsAntithromboticmedicineHumansProspective StudiesAgedLumbar Vertebraebusiness.industryHeparinAnticoagulantGeneral MedicineHeparinHeparin Low-Molecular-WeightMiddle AgedThrombophlebitismedicine.diseaseThrombosisSurgeryRegimenDrug Combinationsmedicine.anatomical_structureAnesthesiaSurgeryFemaleNeurology (clinical)businessDihydroergotamineIntervertebral Disc Displacementmedicine.drugNeurosurgical review
researchProduct

Prophylaxis of radiogenic sialadenitis and mucositis by coumarin/troxerutine in patients with head and neck cancer--a prospective,randomized, placebo…

2001

To study the efficacy of coumarin/troxerutine for the protection of salivary glands and mucosa during irradiation. Design: Prospective, randomized, placebo-controlled, double-blind trial. Setting: University hospital, Germany. Patients: 48 patients who had radiotherapy to the head and neck. Main outcome measures: Salivary gland scintigraphy and acute side-effects of radiotherapy (Radiation Therapy Oncology Group (RTOG) score). Results: 23 patients (11 experimental, 12 placebo) completed the study. The global efficacy measure combining scintigraphy and RTOG score favoured the experimental arm (P= 0.07). The RTOG score showed significantly fewer acute side-effects of radiation in the experime…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentRadiation-Protective AgentsPlaceboGastroenterologyXerostomiaSalivary GlandsSialadenitislaw.inventionRandomized controlled trialDouble-Blind MethodlawCoumarinsInternal medicinemedicineMucositisHumansProspective StudiesProspective cohort studyRadiation InjuriesRadionuclide ImagingAgedSodium Pertechnetate Tc 99mbusiness.industryHead and neck cancerMouth MucosaMiddle Agedmedicine.diseaseSialadenitisSurgeryRadiation therapyDrug CombinationsHydroxyethylrutosideTreatment OutcomeOtorhinolaryngologyEpidermoid carcinomaHead and Neck NeoplasmsSurgeryFemaleOral SurgeryCranial IrradiationRadiopharmaceuticalsbusinessThe British journal of oralmaxillofacial surgery
researchProduct

Efficacy and pharmacological appropriateness of cinnarizine and dimenhydrinate in the treatment of vertigo and related symptoms

2021

Vertigo is not itself a disease, but rather a symptom of various syndromes and disorders that jeopardize balance function, which is essential for daily activities. It is an abnormal sensation of motion that usually occurs in the absence of motion, or when a motion is sensed inaccurately. Due to the complexity of the etiopathogenesis of vertigo, many pharmacological treatments have been tested for efficacy on vertigo. Among these drugs, cinnarizine, usually given together with dimenhydrinate, appears to be the first-line pharmacotherapy for the management of vertigo and inner ear disorders. Based on these considerations, the present non-interventional study aimed to investigate the clinical …

AdultMalepharmacological treatment of vertigomedicine.medical_specialtyCinnarizineHealth Toxicology and MutagenesisDiseasedimenhydrinateArticleCinnarizine Dimenhydrinate Dizziness Pharmacological treatment of vertigo Vertigo Adult Double-Blind Method Drug Combinations Female Histamine H1 Antagonists Humans Male Middle Aged Cinnarizine Dimenhydrinatevertigo03 medical and health sciences0302 clinical medicinePharmacotherapyDouble-Blind MethodVertigoInternal medicinemedicineotorhinolaryngologic diseasesHumans030212 general & internal medicinecinnarizine030223 otorhinolaryngologydizzinessBalance (ability)biologybusiness.industryPublic Health Environmental and Occupational HealthRMiddle Agedbiology.organism_classificationDimenhydrinateDrug CombinationsTolerabilityConcomitantHistamine H1 AntagonistsMedicineFemalebusinessmedicine.drug
researchProduct

Peripheral androgen blockade versus glandular androgen suppression in the treatment of hirsutism.

1991

Hirsutism in women is often explained on the basis of abnormal peripheral androgen metabolism. To determine whether serum markers of ovarian, adrenal, or peripheral androgen production may be helpful determinants in the treatment of hirsutism and to compare the efficacy of treatment with dexamethasone or spironolactone, 20 hyperandrogenic hirsute patients were treated for up to 2 years. Eleven women who were selected on the basis of sensitivity to dexamethasone were treated with a daily dose of 0.37 mg dexamethasone and had androgen levels suppressed into the normal range. Although significant (P less than .05), Ferriman-Gallwey scores decreased only by 20%: 14.2 +/- 0.5 to 11.4 +/- 0.6. Ni…

Adultmedicine.medical_specialtyHirsutismAdolescentmedicine.drug_classmedicine.medical_treatmentSpironolactoneAndrogen suppressionAntiandrogenAndrosteroneDexamethasonechemistry.chemical_compoundInternal medicinemedicineHumansTestosteronehirsutismDexamethasoneChemotherapybusiness.industryDehydroepiandrosterone SulfateAndrostenedioneObstetrics and GynecologyAndrogen AntagonistsDihydrotestosteroneGeneral MedicineDehydroepiandrosteroneAndrogenmedicine.diseaseAndrostane-317-diolDrug CombinationsEndocrinologychemistrySpironolactoneAndrogensCorticosteroidFemalebusinessmedicine.drugObstetrics and gynecology
researchProduct

Abscess of the orbit arising 48 h after root canal treatment of a maxillary first molar

2006

Aim  To discuss a rare, but severe complication arising following routine root canal treatment. Summary  An orbital abscess is reported that occurred following routine root canal treatment. A young, healthy female patient, with no history of chronic paranasal infection had undergone root canal treatment of the right maxillary first molar. On hospital admission, she presented with extensive periorbital swelling and discreet diplopia. Computed tomography imaging identified massive purulent sinusitis and subsequent involvement of the orbit via the inferior and medial orbital wall within 48 h after completion of root canal treatment. Immediate surgical drainage of the maxillary sinus and the or…

Adultmedicine.medical_specialtygenetic structuresMaxillary sinusRoot canalAmoxicillin-Potassium Clavulanate CombinationMetronidazoleMaxillaOrbital DiseasesmedicineMaxillary first molarHumansSinusitisAbscessGeneral DentistryOdontogenic infectionPeriapical periodontitisbusiness.industryMaxillary Sinusitismedicine.diseaseMolarAbscesseye diseasesAnti-Bacterial AgentsRoot Canal TherapySurgeryDrug Combinationsmedicine.anatomical_structureDrainageFemalesense organsGentamicinsTomography X-Ray ComputedbusinessPeriapical PeriodontitisOrbit (anatomy)International Endodontic Journal
researchProduct

Priming with proangiogenic growth factors and endothelial progenitor cells improves revascularization in linear diabetic wounds

2014

In the present study, we investigated whether proangiogenic growth factors and endothelial progenitor cells (EPCs) induce favourable effects on cutaneous incisional wound healing in diabetic mice. The proangiogenic effects of human EPCs were initially analyzed using a HUVEC in vitro angiogenesis assay and an in vivo Matrigel assay in nude mice (n=12). For the diabetic wound model, 48 Balb/c mice with streptozotocin (STZ)-induced diabetes were divided randomly into 4 groups (12 mice in each group). Subsequently, 3, 5 and 7 days before a 15-mm full-thickness incisional skin wound was set, group 1 was pre-treated subcutaneously with a mixture of vascular endothelial growth factor (VEGF)/basic …

Angiogenesismedicine.medical_treatmentBasic fibroblast growth factorMice NudeNeovascularization Physiologicwound healingdiabetic miceDiabetes Mellitus ExperimentalAndrologychemistry.chemical_compoundMiceTensile StrengthGeneticsHuman Umbilical Vein Endothelial CellsMedicineAnimalsHumansProgenitor cellprimingendothelial progenitor cellsMatrigelMice Inbred BALB Cbiologybusiness.industryGrowth factorStem CellsEndothelial CellsGeneral MedicineArticlesVascular endothelial growth factorproangiogenicDrug CombinationschemistryImmunologyMicrovesselsbiology.proteincardiovascular systemIntercellular Signaling Peptides and ProteinsBiological AssayProteoglycansCollagenLamininbusinessWound healingPlatelet-derived growth factor receptorStem Cell TransplantationInternational Journal of Molecular Medicine
researchProduct

Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure

2015

Background— Clinical trials in heart failure have focused on the improvement in symptoms or decreases in the risk of death and other cardiovascular events. Little is known about the effect of drugs on the risk of clinical deterioration in surviving patients. Methods and Results— We compared the angiotensin-neprilysin inhibitor LCZ696 (400 mg daily) with the angiotensin-converting enzyme inhibitor enalapril (20 mg daily) in 8399 patients with heart failure and reduced ejection fraction in a double-blind trial. The analyses focused on prespecified measures of nonfatal clinical deterioration. In comparison with the enalapril group, fewer LCZ696-treated patients required intensification of med…

Angiotensin receptorVascular damage Radboud Institute for Health Sciences [Radboudumc 16]receptorsTetrazolesheart failureAngiotensin-Converting Enzyme InhibitorsKaplan-Meier EstimateSacubitrilAngiotensin; Heart failure; Neprilysin; Receptors; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Double-Blind Method; Enalapril; Heart Failure; Humans; Kaplan-Meier Estimate; Natriuretic Peptide Brain; Neprilysin; Peptide Fragments; Risk Factors; Stroke Volume; Survivors; Tetrazoles; Treatment Outcome; Troponin; Disease Progression; Medicine (all); Cardiology and Cardiovascular Medicine; Physiology (medical)AngiotensinEnalaprilRisk FactorsEnalapril/therapeutic useNatriuretic Peptide BrainHeart Failure/bloodSurvivorsReceptorNeprilysinAminobutyrates: Systèmes cardiovasculaire & respiratoire [D03] [Sciences de la santé humaine]Troponin/bloodTroponinAngiotensin Receptor Antagonists/therapeutic useDrug CombinationsAngiotensin-Converting Enzyme Inhibitors/therapeutic useTreatment OutcomeTetrazoles/therapeutic useCardiologyDisease ProgressionValsartanNeprilysinHeart Failure/blood/drug therapy/physiopathologyCardiology and Cardiovascular Medicinemedicine.drugReceptormedicine.medical_specialtyHeart failureneprilysinAngiotensin Receptor Antagonistsreceptors angiotensinDouble-Blind MethodPhysiology (medical)Internal medicineRenin–angiotensin systemmedicineHumansheart failure neprilysin receptors angiotensinEnalaprilbusiness.industryBiphenyl CompoundsStroke Volumemedicine.diseasePeptide FragmentsEndocrinologyAminobutyrates/therapeutic useStroke Volume/physiologyHeart failureNatriuretic Peptide Brain/blood: Cardiovascular & respiratory systems [D03] [Human health sciences]businessNeprilysin/antagonists & inhibitorsPeptide Fragments/bloodSacubitril ValsartanBiomarkersBiomarkers/blood
researchProduct

Influence of a bioceramic root end material and mineral trioxide aggregates on fibroblasts and osteoblasts

2012

The biocompatibility of materials used in endodontic treatment is of high importance, because they can come in contact with periradicular tissues and there is a risk of possible systemic toxicity. The aim of the present study was to investigate the in vitro reaction to a bioceramic based root end material in comparison to mineral trioxide aggregates (MTA) as the established gold standard.The root end materials grey MTA Angelus (GMTA), white MTA Angelus (WMTA), ProRoot MTA, and EndoSequence Root Repair Material (ERRM) were incubated with human periodontal ligament fibroblasts and osteoblasts (10(4)cells/ml) for up to 96h. Cell proliferation (RFU) was determined by means of the Alamar Blue as…

BiocompatibilityPeriodontal LigamentCell Culture TechniquesDentistryBiocompatible MaterialsBioceramicRoot Canal Filling Materialschemistry.chemical_compoundHumansAluminum CompoundsGeneral DentistryCell ProliferationOsteoblastsbusiness.industrySilicatesOxidesCell BiologyGeneral MedicineCalcium CompoundsFibroblastsDrug CombinationsPeriradicularSystemic toxicityOtorhinolaryngologychemistryBiological AssaybusinessTrioxideArchives of Oral Biology
researchProduct